{"id":703566,"date":"2010-03-25T10:14:52","date_gmt":"2010-03-25T14:14:52","guid":{"rendered":"tag:www.hepatitis-central.com,2010:\/mt\/\/1.793"},"modified":"2010-03-29T10:18:03","modified_gmt":"2010-03-29T14:18:03","slug":"preferred-dosing-schedule-pledged-by-hcv-drug-candidate","status":"publish","type":"post","link":"https:\/\/mereja.com\/index\/703566","title":{"rendered":"Preferred Dosing Schedule Pledged by HCV Drug Candidate"},"content":{"rendered":"<p>Zalbin is a Hepatitis C drug in development that could lead to the highly desired monthly or bi-monthly dosing.<\/p>\n<p>Human Genome Sciences reports hepatitis drug study<\/p>\n<p>The Associated Press  March 24, 2010<\/p>\n<p>ROCKVILLE, Md.<\/p>\n<p>Human Genome Sciences Inc. said Wednesday a midstage study of the potential hepatitis C treatment Zalbin showed a monthly dose of the drug candidate could be as effective as a weekly dose of the standard treatment.<\/p>\n<p>Continue reading this entire article:<br \/>\n<a href=\"http:\/\/www.businessweek.com\/ap\/financialnews\/D9EL00D82.htm\">http:\/\/www.businessweek.com\/ap\/financialnews\/D9EL00D82.htm<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zalbin is a Hepatitis C drug in development that could lead to the highly desired monthly or bi-monthly dosing. Human Genome Sciences reports hepatitis drug study The Associated Press March 24, 2010 ROCKVILLE, Md. Human Genome Sciences Inc. said Wednesday a midstage study of the potential hepatitis C treatment Zalbin showed a monthly dose of [&hellip;]<\/p>\n","protected":false},"author":288,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[4821],"tags":[],"class_list":["post-703566","post","type-post","status-publish","format-standard","hentry","category-news"],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p9NivD-2X1Q","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/703566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/users\/288"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/comments?post=703566"}],"version-history":[{"count":0,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/703566\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/media?parent=703566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/categories?post=703566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/tags?post=703566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}